These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8767349)

  • 21. Candesartan cilexetil: a review of its preclinical pharmacology.
    Nishikawa K; Naka T; Chatani F; Yoshimura Y
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S9-17. PubMed ID: 9330999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man.
    Mizojiri K; Okabe H; Sugeno K; Misaki A; Ito M; Kominami G; Esumi Y; Takaichi M; Harada T; Seki H; Inaba A
    Arzneimittelforschung; 1997 Mar; 47(3):259-69. PubMed ID: 9105544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 1st communication: absorption, pharmacokinetics and excretion in rats and dogs.
    Yamada Y; Endo M; Kohno M; Otsuka M; Takaiti O
    Arzneimittelforschung; 1992 Apr; 42(4):457-65. PubMed ID: 1642668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats.
    Fujii T; Matsumoto S; Amejima H; Hatoyama T; Nakao M; Kagemoto A; Tanaka K; Miyazaki H
    Arzneimittelforschung; 1994 Apr; 44(4):527-38. PubMed ID: 7912071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic disposition of 6-ethyl-3-(1H-tetrazol-5-yl)-chromone, a new antiallergic agent, in the rat, guinea-pig, rabbit, dog and monkey.
    Kanai Y; Nakai Y; Nakajima N; Tanayama S
    Xenobiotica; 1979 Jan; 9(1):33-50. PubMed ID: 104449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
    Kakizawa H; Itoh Y; Imamura S; Matsumoto T; Ishiwata Y; Ono Y; Yamamoto K; Kato T; Hayakawa N; Oda N; Goto Y; Goto Y; Nagasaka A; Senda T; Itoh M
    Horm Metab Res; 2004 Jul; 36(7):458-64. PubMed ID: 15305228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disposition of DN-2327, a new anxiolytic, in rats, dogs, and monkeys.
    Kondo T; Kurata Y; Yoshida K; Yoshimura Y
    Biol Pharm Bull; 1995 Feb; 18(2):330-6. PubMed ID: 7742808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic drug interaction studies with candesartan cilexetil.
    Jonkman JH; van Lier JJ; van Heiningen PN; Lins R; Sennewald R; Högemann A
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S31-5. PubMed ID: 9331003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical pharmacokinetics of candesartan.
    Gleiter CH; Mörike KE
    Clin Pharmacokinet; 2002; 41(1):7-17. PubMed ID: 11825094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties.
    Kito G; Morimoto S; Shiomi M
    Arzneimittelforschung; 1996 Jun; 46(6):572-9. PubMed ID: 8767346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
    Mukai H; Sugimoto T; Ago M; Morino A
    Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The disposition of radioactivity after administration of the anthelminthic methyl-14C-5-cyclopropylcarbonyl-2-benzimidazole carbamate (ciclobendazole) to rats and dogs.
    Brodie RR; Mayo BC; Chasseaud LF; Hawkins DR
    Arzneimittelforschung; 1977; 27(3):593-8. PubMed ID: 577426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
    Mitrovic V; Willenbrock R; Miric M; Seferovic P; Spinar J; Dabrowski M; Kiowski W; Marks DS; Alegria E; Dukát A; Lenz K; Arens HA
    Am Heart J; 2003 Mar; 145(3):E14. PubMed ID: 12660683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats.
    Inada Y; Wada T; Shibouta Y; Ojima M; Sanada T; Ohtsuki K; Itoh K; Kubo K; Kohara Y; Naka T
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1540-7. PubMed ID: 8138966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disposition of a low dose of 14C-bisphenol A in male rats and its main biliary excretion as BPA glucuronide.
    Kurebayashi H; Betsui H; Ohno Y
    Toxicol Sci; 2003 May; 73(1):17-25. PubMed ID: 12700409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers.
    Belz GG; Fuchs B; Malerczyk C; Magin SG; Roll S; Mutschler E
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S45-7. PubMed ID: 9331006
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
    Bönner G; Fuchs W
    Curr Med Res Opin; 2005 Jun; 21(6):935-40. PubMed ID: 15969893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 1st communication: absorption, concentrations in plasma, metabolism, and excretion after single administration to rats and dogs.
    Boberg M; Ahr HJ; Beckermann B; Bühner K; Siefert HM; Steinke W; Wünsche C; Hirayama M
    Arzneimittelforschung; 1997 Aug; 47(8):928-38. PubMed ID: 9296279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia.
    Fu H; Hosomi N; Pelisch N; Nakano D; Liu G; Ueno M; Miki T; Masugata H; Sueda Y; Itano T; Matsumoto M; Nishiyama A; Kohno M
    J Hypertens; 2011 Nov; 29(11):2210-9. PubMed ID: 21934531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacokinetics of epristeride in rats and beagle dogs].
    Wei GL; Xiao SH; Liu CX
    Yao Xue Xue Bao; 2000 Oct; 35(10):721-4. PubMed ID: 11372434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.